Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2442592 | 0.86 | NPC1 (0.69) | NPC1RAB9APOLBTP53MAPT | |
| SCHEMBL1583201 | 0.81 | PTGS1 (0.66) | NPC1RAB9APOLBTP53MAPT | |
| SCHEMBL2436563 | 0.78 | RAB9A (0.69) | NPC1RAB9APOLBTP53MAPT | |
| SCHEMBL2435738 | 0.76 | RAB9A (0.58) | NPC1RAB9APOLBMAPTCYP1A2 | |
| SCHEMBL2468923 | 0.76 | RAB9A (1.00) | NPC1RAB9APOLBTDP1MAPT | |
| SCHEMBL15924280 | 0.76 | MAPT (0.72) | NPC1RAB9APOLBTP53MAPT | |
| SCHEMBL23657493 | 0.74 | RAB9A (0.80) | NPC1RAB9APOLBTP53MAPT | |
| SCHEMBL17903825 | 0.74 | NPC1 (0.59) | NPC1RAB9APOLBTP53MAPT | |
| SCHEMBL11446166 | 0.73 | POLB (0.60) | NPC1RAB9APOLBTDP1TP53 | |
| SCHEMBL4620787 | 0.73 | MAPT (1.00) | NPC1RAB9APOLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225241-B1 | Derivatives of N-phenyl-imidazo-(1,2-A)-pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-09-14 | — | — | EP | claimed |
| US-20100317685-A1 | N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| CN-101910176-A | N-phenylimidazo [1,2-a ] pyridine-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2010-12-08 | — | — | CN | claimed |
| US-20100317685-A1 | N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| CN-101910176-A | N-phenylimidazo [1,2-a ] pyridine-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2010-12-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317685-A1 | N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | ARG2, IDH2, GLS | NPC1 643/4885RAB9A 1246/4885POLB 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.